Corbus Pharmaceuticals (CRBP) Competitors $10.27 +0.90 (+9.61%) Closing price 09/16/2025 04:00 PM EasternExtended Trading$10.53 +0.26 (+2.52%) As of 09/16/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CRBP vs. CMPX, ETON, ALMS, PRTA, CRVS, ERAS, ITOS, SLDB, ATXS, and NBTXShould you be buying Corbus Pharmaceuticals stock or one of its competitors? The main competitors of Corbus Pharmaceuticals include Compass Therapeutics (CMPX), Eton Pharmaceuticals (ETON), Alumis (ALMS), Prothena (PRTA), Corvus Pharmaceuticals (CRVS), Erasca (ERAS), iTeos Therapeutics (ITOS), Solid Biosciences (SLDB), Astria Therapeutics (ATXS), and Nanobiotix (NBTX). These companies are all part of the "pharmaceutical products" industry. Corbus Pharmaceuticals vs. Its Competitors Compass Therapeutics Eton Pharmaceuticals Alumis Prothena Corvus Pharmaceuticals Erasca iTeos Therapeutics Solid Biosciences Astria Therapeutics Nanobiotix Compass Therapeutics (NASDAQ:CMPX) and Corbus Pharmaceuticals (NASDAQ:CRBP) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations, profitability and earnings. Does the media favor CMPX or CRBP? In the previous week, Corbus Pharmaceuticals had 3 more articles in the media than Compass Therapeutics. MarketBeat recorded 6 mentions for Corbus Pharmaceuticals and 3 mentions for Compass Therapeutics. Corbus Pharmaceuticals' average media sentiment score of 1.87 beat Compass Therapeutics' score of 0.99 indicating that Corbus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compass Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Corbus Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Which has more risk & volatility, CMPX or CRBP? Compass Therapeutics has a beta of 1.5, meaning that its stock price is 50% more volatile than the S&P 500. Comparatively, Corbus Pharmaceuticals has a beta of 3.08, meaning that its stock price is 208% more volatile than the S&P 500. Do insiders & institutionals believe in CMPX or CRBP? 68.4% of Compass Therapeutics shares are held by institutional investors. Comparatively, 64.6% of Corbus Pharmaceuticals shares are held by institutional investors. 29.8% of Compass Therapeutics shares are held by company insiders. Comparatively, 4.0% of Corbus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Do analysts recommend CMPX or CRBP? Compass Therapeutics currently has a consensus target price of $13.88, suggesting a potential upside of 284.35%. Corbus Pharmaceuticals has a consensus target price of $49.00, suggesting a potential upside of 377.12%. Given Corbus Pharmaceuticals' higher possible upside, analysts plainly believe Corbus Pharmaceuticals is more favorable than Compass Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Compass Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11Corbus Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 3.10 Is CMPX or CRBP more profitable? Corbus Pharmaceuticals' return on equity of -43.65% beat Compass Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Compass TherapeuticsN/A -53.11% -46.14% Corbus Pharmaceuticals N/A -43.65%-39.62% Which has better earnings and valuation, CMPX or CRBP? Corbus Pharmaceuticals has lower revenue, but higher earnings than Compass Therapeutics. Compass Therapeutics is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCompass Therapeutics$850K587.28-$49.38M-$0.45-8.02Corbus PharmaceuticalsN/AN/A-$40.21M-$4.76-2.16 SummaryCorbus Pharmaceuticals beats Compass Therapeutics on 9 of the 14 factors compared between the two stocks. Get Corbus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRBP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CRBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRBP vs. The Competition Export to ExcelMetricCorbus PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$114.83M$2.55B$5.73B$10.31BDividend YieldN/A60.31%5.90%4.63%P/E Ratio-2.1623.4975.8626.51Price / SalesN/A672.77528.72123.58Price / CashN/A169.4937.1760.46Price / Book0.885.3312.796.29Net Income-$40.21M$32.95M$3.28B$270.51M7 Day Performance6.31%0.10%0.81%1.95%1 Month Performance11.03%3.91%4.60%6.33%1 Year Performance-79.82%-3.91%70.39%25.62% Corbus Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRBPCorbus Pharmaceuticals4.3818 of 5 stars$10.27+9.6%$49.00+377.1%-80.9%$114.83MN/A-2.1640News CoveragePositive NewsGap UpHigh Trading VolumeCMPXCompass Therapeutics2.2353 of 5 stars$3.44flat$12.89+274.7%+111.1%$475.69M$850K-7.6420Positive NewsETONEton Pharmaceuticals2.2879 of 5 stars$17.78+0.6%$29.67+66.9%+219.3%$473.87M$39.01M-111.1320Positive NewsALMSAlumis3.2809 of 5 stars$4.32-4.2%$20.17+366.8%-62.4%$469.33MN/A0.00N/APositive NewsPRTAProthena3.408 of 5 stars$8.49-0.7%$19.75+132.6%-62.7%$460.25M$135.16M-1.51130News CoverageAnalyst RevisionCRVSCorvus Pharmaceuticals2.4803 of 5 stars$5.90-4.2%$15.00+154.2%-0.7%$459.01MN/A-5.8430Positive NewsERASErasca2.3672 of 5 stars$1.55-3.7%$3.71+139.6%-39.4%$456.71MN/A-3.44120Analyst DowngradeITOSiTeos Therapeutics3.427 of 5 stars$10.15flat$15.50+52.7%N/A$448.73M$35M-2.1790Positive NewsSLDBSolid Biosciences3.1018 of 5 stars$5.13-6.7%$15.00+192.4%-28.2%$428.28M$8.09M-1.83100Positive NewsAnalyst DowngradeATXSAstria Therapeutics2.8467 of 5 stars$7.43-1.2%$29.00+290.3%-35.3%$424.39MN/A-3.7030Positive NewsNBTXNanobiotix0.6225 of 5 stars$8.71+0.1%$8.00-8.2%+97.6%$417.11M$39.18M0.00100Upcoming EarningsShort Interest ↑Gap Up Related Companies and Tools Related Companies CMPX Alternatives ETON Alternatives ALMS Alternatives PRTA Alternatives CRVS Alternatives ERAS Alternatives ITOS Alternatives SLDB Alternatives ATXS Alternatives NBTX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRBP) was last updated on 9/17/2025 by MarketBeat.com Staff From Our PartnersREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corbus Pharmaceuticals Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Corbus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CRBP Stock Alerts